Christopher Bunker

Christopher Bunker

Company: Alamar Biosciences Inc.

Job title: Vice President, Biopharma Business Development


NULISA: Ultra-sensitive & Multiplex Immunoassay Platform for Fluid Biomarkers in CNS Disease 9:30 am

New biomarker assay technology, NULISA™ – with ultra-sensitive femtogram level detection with proprietary background suppression technology Unique NULISA CNS Disease Panel detecting nearly 120 critical biomarkers covering diverse neurological diseases Ultra-sensitive NULISA technology holds great promise to enable early detection and monitoring of neurodegenerative diseases to aid in new therapeutic development.Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.